Boston Scientific Corporation
BSX
$103.05
-$0.245-0.24%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.55B | 16.75B | 15.91B | 15.23B | 14.71B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.55B | 16.75B | 15.91B | 15.23B | 14.71B |
| Cost of Revenue | 5.54B | 5.29B | 4.97B | 4.77B | 4.56B |
| Gross Profit | 12.02B | 11.46B | 10.94B | 10.46B | 10.15B |
| SG&A Expenses | 6.22B | 5.98B | 5.75B | 5.43B | 5.34B |
| Depreciation & Amortization | 862.00M | 857.00M | 840.00M | 843.00M | 840.00M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.31B | 13.75B | 13.08B | 12.51B | 12.18B |
| Operating Income | 3.24B | 3.00B | 2.83B | 2.72B | 2.53B |
| Income Before Tax | 2.48B | 2.28B | 2.20B | 2.14B | 2.15B |
| Income Tax Expenses | 454.00M | 436.00M | 414.00M | 319.00M | 377.00M |
| Earnings from Continuing Operations | 2.03K | 1.85K | 1.79K | 1.83K | 1.77K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 8.00M | 7.00M | 4.00M | 4.00M | 2.00M |
| Net Income | 2.03B | 1.85B | 1.79B | 1.83B | 1.78B |
| EBIT | 3.24B | 3.00B | 2.83B | 2.72B | 2.53B |
| EBITDA | 4.53B | 4.27B | 4.06B | 3.95B | 3.74B |
| EPS Basic | 1.38 | 1.26 | 1.22 | 1.25 | 1.21 |
| Normalized Basic EPS | 1.27 | 1.18 | 1.10 | 1.05 | 0.96 |
| EPS Diluted | 1.37 | 1.25 | 1.21 | 1.23 | 1.19 |
| Normalized Diluted EPS | 1.25 | 1.16 | 1.09 | 1.04 | 0.95 |
| Average Basic Shares Outstanding | 5.89B | 5.89B | 5.88B | 5.87B | 5.84B |
| Average Diluted Shares Outstanding | 5.95B | 5.94B | 5.93B | 5.92B | 5.89B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | 0.00% | 0.00% | 0.79% |